A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled Study of AGN-151586 in the Treatment of Japanese Subjects With Moderate to Severe Glabellar Lines
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Botulinum toxin E (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 04 Mar 2024 Planned End Date changed from 10 Apr 2024 to 9 Apr 2024.
- 04 Mar 2024 Planned primary completion date changed from 7 Mar 2024 to 9 Apr 2024.